Nasus Pharma Ltd.: updates and filings

NSRXAMEXHealthcare · Pharmaceutical Preparations

Price

$2.55

November 19, 2026Market cap $23M

What Ploutos Investor adds for Nasus Pharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history in every section
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 25, 2026 latest annual
  • Nov 16, 2026Current report (foreign company)
    Form6-K
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 19, 2026Shares registered for employees
    FormS-8
  • Oct 8, 2026Current report (foreign company)
    Form6-K
  • Sep 18, 2026Current report (foreign company)
    Form6-K
  • Sep 14, 2026Current report (foreign company)
    Form6-K
  • Sep 11, 2026Filing
    FormEFFECT
  • Sep 4, 2026Current report (foreign company)
    Form6-K
  • Sep 1, 2026Filing
    FormF-3
  • Aug 20, 2026Filing
    FormEFFECT
  • Aug 19, 2026Current report (foreign company)
    Form6-K
  • Aug 19, 2026Filing
    FormPOS AM
  • Aug 17, 2026Current report (foreign company)
    Form6-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 28, 2026Current report (foreign company)
    Form6-K
  • Jun 9, 2026Current report (foreign company)
    Form6-K
  • May 26, 2026Shares registered for employees
    FormS-8
  • May 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Apr 7, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Mar 31, 2026Filing
    FormEFFECT
  • Mar 27, 2026Filing
    FormPOS AM
  • Mar 25, 2026Current report (foreign company)
    Form6-K
  • Mar 25, 2026Annual report (foreign company)for the period to Dec 31, 2025
    Form20-F
  • Mar 16, 2026Current report (foreign company)
    Form6-K
  • Mar 13, 2026Filing
    FormEFFECT

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 30, 2024.

The full analysis

What do Nasus Pharma's filings show?

The filings are where every one of Nasus Pharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.